{"entity":{"id":"sinorda","kind":"company","name":"Sinorda","aka":["Guizhou Sinorda Pharmaceutical Co., Ltd.","Guizhou Sinorda Biomedicine","生诺医药"],"tldr":"Sinorda is a Chinese drug company, already selling a stomach-acid medicine, that is testing a cell therapy made from a patient's own T cells taken from the lymph nodes nearest the tumour.","summary":"Guizhou Sinorda Pharmaceutical Co., Ltd. (生诺医药), in the Guiyang national high-tech zone, was founded in 2010 according to the company and is a commercial-stage company focused on digestive disease, tumour immunology and autoimmune disease; its acid-related disease drug linaprazan glurate (X842) is approved in China. In oncology, its Lymph-T Exp platform expands tumour-reactive T cells from sentinel lymph nodes, which the company says has investigator-initiated clinical results in several tumours. SND002 Cell Injection, an autologous T cell product, is in a phase 1 study in advanced solid tumours including colorectal and gastric cancer (NCT07903857). Its first registered cancer trial, NCT07903857, was posted on ClinicalTrials.gov in October 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.sinorda.com/"},{"label":"About","url":"https://www.sinorda.com/About.html"},{"label":"ClinicalTrials.gov: phase 1 trial of SND002 (NCT07903857)","url":"https://clinicaltrials.gov/study/NCT07903857"}],"tags":[],"related":[],"cancers":["colorectal","gastric"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website (Chinese) read on 29 October 2026. Oncology is one of three focus areas; the company was kept because SND002 is its own cell therapy. The TIL therapy technology tag is the nearest fit for lymph-node-derived T cells. No financing amounts read."],"hq":"Guiyang","country":"CN","companyType":"pharma","website":"https://www.sinorda.com/","founded":2010,"stage":"growth","investors":[],"funding":[]},"route":"/companies/sinorda/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}]}}